2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis^†

Mark RenzProthena Biosciences Inc, South San Francisco, CA, USA

Ronald TorresProthena Biosciences Inc, South San Francisco, CA, USA

Philip J. DolanProthena Biosciences Inc, South San Francisco, CA, USA

Stephen J. TamProthena Biosciences Inc, South San Francisco, CA, USA

Jose R. TapiaProthena Biosciences Inc, South San Francisco, CA, USA

Lauri LiProthena Biosciences Inc, South San Francisco, CA, USA

Joshua R. SalmansProthena Biosciences Inc, South San Francisco, CA, USA

Robin M. BarbourProthena Biosciences Inc, South San Francisco, CA, USA

Paul J. ShughrueProthena Biosciences Inc, South San Francisco, CA, USA

Tarlochan NijjarProthena Biosciences Inc, South San Francisco, CA, USA

Dale SchenkProthena Biosciences Inc, South San Francisco, CA, USA

Gene G. KinneyProthena Biosciences Inc, South San Francisco, CA, USA

Wagner ZagoProthena Biosciences Inc, South San Francisco, CA, USACorrespondence[email protected]

Related Research Data